The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Open accessAbstract
BACKGROUND: Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples. METHODS: To examine intratumor heterogeneity, we performed exome sequencing, chromosome aberration analysis, and ploidy profiling on multiple spatially separated samples obtained from primary renal carcinomas and associated metastatic sites. We characterized the consequences of intratumor heterogeneity using immunohistochemical analysis, mutation functional analysis, and profiling of messenger RNA expression. RESULTS: Phylogenetic reconstruction revealed branched evolutionary tumor growth, with 63 to 69% of all somatic mutations not detectable across every tumor region. Intratumor heterogeneity was observed for a mutation within an autoinhibitory domain of the mammalian target of rapamycin (mTOR) kinase, correlating with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro. Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially separated inactivating mutations within a single tumor, suggesting convergent phenotypic evolution. Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor. Allelic composition and ploidy profiling analysis revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples from four tumors harboring divergent allelic-imbalance profiles and with ploidy heterogeneity in two of four tumors. CONCLUSIONS: Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development. Intratumor heterogeneity, associated with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection. (Funded by the Medical Research Council and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A greater degree of divergence may be attributed to intra-tumor spatial heterogeneity and sampling bias: tumors can be spatially diverse, and organoids generated from a specific portion may lack the representativeness of distant regions130,131.”
From Organoids (2022) · cites this paper as [130]
Experimental — accuracy not yet measuredIn the citing paper
“a small needle biopsy of a single lesion may fail to reflect the true underlying intra- and inter-tumor genetic heterogeneity (15–17).”
In the citing paper
“It is now appreciated that most clinically relevant solid tumors are highly heterogeneous at the phenotypic, physiologic, and genomic levels (13–15) and that they continue to evolve over time.”
From Radiomics: Images Are More than Pictures, They Are Data (2016) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Cancer as an evolutionary and ecological process
Merlo, L. M. F., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2013 · Cited by 1,743
Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Munshi, N. C., & Crawford, E. D. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003013 · Cited by 1,710
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Cited by
Sorted by citations
Items 501–600 of 1,049
Chronic lymphocytic leukaemia: from genetics to treatment
Bosch, F., & Dalla‐Favera, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0239-8 · Cited by 259
Therapeutic Targeting of Cancers with Loss of PTEN Function
Dillon, L. M., & Miller, T. W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106100909 · Cited by 246
Cancer immunotherapy: broadening the scope of targetable tumours
van den Bulk, J., Verdegaal, E. M. E., & de Miranda, N. F. C. C. (2018) · Open Biology · doi:10.1098/rsob.180037 · Cited by 244
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
de Castro, D. G., Clarke, P. A., Al‐Lazikani, B., & Workman, P. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.237 · Cited by 237
Stenzinger, A., Allen, J. D., Maas, J., Stewart, M. D., Merino, D. M., Wempe, M. M., & Dietel, M. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22733 · Cited by 245
“neity, with subclonal events having a higher impact on mutational burden than clonal evolution.(3,39,45,46) Additionally, tumor transcriptional”
BackgroundWu, L. L., Yan, J., Bai, Y., Chen, F., Zou, X., Xu, J., Huang, A., Hou, L., Zhong, Y., Jing, Z., et al. (2023) · Cell Research · doi:10.1038/s41422-023-00831-1 · Cited by 253
Evolutionary biology of high-risk multiple myeloma
Pawlyn, C., & Morgan, G. J. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.63 · Cited by 242
Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
Jankú, F., Hong, D. S., Fu, S., Piha-Paul, S. A., Naing, A., Falchook, G. S., Tsimberidou, A. M., Stepanek, V. M. T., Moulder, S., Lee, J. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.035 · Cited by 237
Menares, E., Gálvez‐Cancino, F., Morgado-Cáceres, P., Ghorani, E., López, E., Díaz, X., Saavedra-Almarza, J., Figueroa, D. A., Roa, E., Quezada, S. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12319-x · Cited by 255
“Indeed, tumor-cell exon sequencing has revealed that multiple regions inside the same tumor or different lesions in the same patient have divergent mutation patterns 55,56 and probably a differential expression of antigens.”
Fan, J., Lee, H., Lee, S., Ryu, D., Lee, S., Xue, C., Kim, S. J., Kım, K., Barkas, N., Park, P. J., et al. (2018) · Genome Research · doi:10.1101/gr.228080.117 · Cited by 228
“While some of the alterations have been tied to perturbations of known oncogenes and tumor suppressors, such as MYC and TP53 (Sekiguchi et al. 2014; Glitza et al. 2015), the process by which manygenetic alterations impact transcriptional processes to drive disease progression and drug resistance,…”
Inferring clonal evolution of tumors from single nucleotide somatic mutations
Jiao, W., Vembu, S., Deshwar, A. G., Stein, L. D., & Morris, Q. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-35 · Cited by 242
Pharmacogenomics: Driving Personalized Medicine
Sadée, W., Wang, D., Hartmann, K., & Toland, A. E. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000810 · Cited by 264
Targeting Breast Cancer Metastasis
Jin, X., & Mu, P. (2015) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s25460 · Cited by 250
Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target
Jackson, M., Hassiotou, F., & Nowak, A. K. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu243 · Cited by 246
Towards individualized therapy for metastatic renal cell carcinoma
Kotecha, R. R., Motzer, R. J., & Voss, M. H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0209-1 · Cited by 236
Melchor, L., Brioli, A., Wardell, C. P., Murison, A., Potter, N. E., Kaiser, M., Fryer, R. A., Johnson, D. C., Begum, D. B., Wilson, S. H., et al. (2014) · Leukemia · doi:10.1038/leu.2014.13 · Cited by 237
Rothé, F., Laes, J., Lambrechts, D., Smeets, D., Vincent, D., Maetens, M., Fumagalli, D., Michiels, S., Drisis, S., Moerman, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu288 · Cited by 235
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
Koikawa, K., Kibe, S., Suizu, F., Sekino, N., Kim, N., Manz, T. D., Pinch, B. J., Akshinthala, D., Verma, A., Gaglia, G., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.020 · Cited by 243
Antibody‐Drug Conjugates for the Treatment of Cancer
Flygare, J. A., Pillow, T. H., & Aristoff, P. A. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12085 · Cited by 232
Hakimi, A. A., Chen, Y., Wren, J. M., Gönen, M., Abdel-Wahab, O. I., Heguy, A., Liu, H., Takeda, S., Tickoo, S. K., Reuter, V. E., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.09.005 · Cited by 236
Connor, A. A., Denroche, R. E., Jang, G. H., Lemire, M., Zhang, A. X. W., Chan‐Seng‐Yue, M., Wilson, G. W., Grant, R. C., Merico, D., Lungu, I. M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.010 · Cited by 227
Kwiatkowski, D. J., Choueiri, T. K., Fay, A. P., Rini, B. I., Thorner, A. R., de Velasco, G., Tyburczy, M. E., Hamieh, L., Albiges, L. K., Agarwal, N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2631 · Cited by 232
“However, studies of heterogeneity have reported that different cancer specimens derived from a single patient often have convergent mutations that result in activation of the same gene/ pathway in different tumor samples (22, 47).”
BackgroundHeemskerk, B., Kvistborg, P., & Schumacher, T. N. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.333 · Cited by 239
Fast and scalable inference of multi-sample cancer lineages
Popic, V., Salari, R., Hajirasouliha, I., Kashef-Haghighi, D., West, R. B., & Batzoglou, S. (2015) · Genome biology · doi:10.1186/s13059-015-0647-8 · Cited by 231
THetA: inferring intra-tumor heterogeneity from high-throughput DNA sequencing data
Oesper, L., Mahmoody, A., & Raphael, B. J. (2013) · Genome biology · doi:10.1186/gb-2013-14-7-r80 · Cited by 229
Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Iglesias, V. S., Giuranno, L., Dubois, L. J., Theys, J., & Vooijs, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00267 · Cited by 233
“It was first exemplified in renal cancer that biopsies from primary and metastatic sites from the same patient showed extensive divergent and convergent evolution of driver mutations, copy number variations, and chromosome aneuploidy (31).”
BackgroundClinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 241
Pros: Can tissue biopsy be replaced by liquid biopsy?
Ilié, M., & Hofman, P. M. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.08.06 · Cited by 239
“First, comprehensive characterization of multiple tumor specimens obtained from the same patient illustrated that intratumor heterogeneity exists between different regions in the same tumor (spatial heterogeneity), as well as between the primary tumor and local or distant recurrences in the same patient (temporal hete…”
BackgroundZheng, D., Ye, X.-R., Zhang, M. Z., Sun, Y., Wang, J. Y., Ni, J., Zhang, H. P., Zhang, L., Luo, J., Zhang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep20913 · Cited by 229
Integrating evolutionary dynamics into cancer therapy
Gatenby, R. A., & Brown, J. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0411-1 · Cited by 227
Khan, K. H., Cunningham, D., Werner, B., Vlachogiannis, G., Spiteri, I., Heide, T., Fernández-Mateos, J., Vatsiou, A. I., Lampis, A., Darvish-Damavandi, M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0891 · Cited by 227
The influence of subclonal resistance mutations on targeted cancer therapy
Schmitt, M. W., Loeb, L. A., & Salk, J. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.175 · Cited by 234
Overview on Clinical Relevance of Intra-Tumor Heterogeneity
Stanta, G., & Bonin, S. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00085 · Cited by 227
“More recently, it has been clearly shown that this is the case in cancer (21).”
BackgroundHiley, C. T., de Bruin, E. C., McGranahan, N., & Swanton, C. (2014) · Genome biology · doi:10.1186/s13059-014-0453-8 · Cited by 233
Self-citationShu, Y., Wu, X., Tong, X., Wang, X., Chang, Z., Mao, Y., Chen, X., Sun, J., Wang, Z., Hong, Z., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00520-1 · Cited by 226
Cancer Genome Evolutionary Trajectories in Metastasis
Birkbak, N. J., & McGranahan, N. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.004 · Cited by 223
Li, Y., Lih, T. M., Dhanasekaran, S. M., Mannan, R., Chen, L., Cieslik, M. P., Wu, Y., Lu, R. J.-H., Clark, D. J., Kołodziejczak, I., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.12.001 · Cited by 237
From single cells to deep phenotypes in cancer
Bendall, S. C., & Nolan, G. P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2283 · Cited by 225
Shaw, J., Guttery, D. S., Hills, A., Fernández-García, D., Page, K., Rosales, B. M., Goddard, K. S., Hastings, R. K., Luo, J., Ogle, O., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0825 · Cited by 225
“Taking all these considerations into account, together with the well-established phenomenon of clonal evolution (16, 17), it is evident that a single conventional tissue biopsy will not necessarily provide accurate information regarding appropriate therapy.”
BackgroundReconstruction of clonal trees and tumor composition from multi-sample sequencing data
El-Kebir, M., Oesper, L., Acheson-Field, H., & Raphael, B. J. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv261 · Cited by 219
“These studies measure somatic mutations in multiple spatially distinct regions from the same tumor at a single time point (Gerlinger et al., 2012, 2014; Newburger et al., 2013; Zhang et al., 2014) or measure a tumor at multiple time points (Schuh et al., 2012).”
BackgroundSingle-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancerPreprint
Leung, M. L., Davis, A., Gao, R., Casasent, T. D., Wang, Y., Sei, E., Vilar, E., Maru, D. M., Kopetz, S., & Navin, N. E. (2017) · Genome Research · doi:10.1101/gr.209973.116 · Cited by 220
“www.genome.org cell (Gerlinger et al. 2012; Yates and Campbell 2012; Newburger et al. 2013; Wang et al. 2014; Zhang et al. 2014; McPherson et al. 2016).”
Mroz, E. A., Tward, A. D., Pickering, C. R., Myers, J. N., Ferris, R. L., & Rocco, J. W. (2013) · Cancer · doi:10.1002/cncr.28150 · Cited by 227
Cellular Potts Modeling of Tumor Growth, Tumor Invasion, and Tumor Evolution
Szabó, A., & Merks, R. M. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00087 · Cited by 221
Caswell, D. R., & Swanton, C. (2017) · BMC Medicine · doi:10.1186/s12916-017-0900-y · Cited by 225
Self-citationThe evolutionary dynamics of extrachromosomal DNA in human cancers
Lange, J. T., Rose, J. C., Chen, C. Y., Pichugin, Y., Xie, L., Tang, J., Hung, K. L., Yost, K. E., Shi, Q., Erb, M. L., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01177-x · Cited by 226
Self-citationRaphael, B. J., Dobson, J. R., Oesper, L., & Vandin, F. (2014) · Genome Medicine · doi:10.1186/gm524 · Cited by 226
Powley, I. R., Patel, M., Miles, G. J., Pringle, H., Howells, L. M., Thomas, A., Kettleborough, C. A., Bryans, J. S., Hammonds, T. R., MacFarlane, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0672-6 · Cited by 230
Leijenaar, R. T. H., Carvalho, S., Hoebers, F. J. P., Aerts, H. J. W. L., van Elmpt, W., Huang, S. H., Chan, H. B., Waldron, J. N., O’Sullivan, B., & Lambin, P. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1061214 · Cited by 216
“invasiveness and probability of misrepresenting the entire tumor due to intra-tumor heterogeneity, as they only characterize a small portion of the tumor [10].”
BackgroundWu, J., Cao, G., Sun, X., Lee, J., Rubin, D. L., Napel, S. A., Kurian, A. W., Daniel, B. L., & Li, R. (2018) · Radiology · doi:10.1148/radiol.2018172462 · Cited by 216
“It has been recognized that tumors demonstrate regional variations in genotypes and phenotypes owing to clonal evolution (28,29).”
BackgroundWang, Z., Cheng, Y., An, T., Gao, H., Wang, K., Zhou, Q. H., Hu, Y., Song, Y., Ding, C., Peng, F., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30264-9 · Cited by 217
Couraud, S., Vaca-Paniagua, F., Villar, S., Oliver, J., Schuster, T., Blanché, H., Girard, N., Trédaniel, J., Guilleminault, L., Gervais, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3063 · Cited by 215
Hsp90, an unlikely ally in the war on cancer
Barrott, J. J., & Haystead, T. (2013) · FEBS Journal · doi:10.1111/febs.12147 · Cited by 225
Extracellular Vesicles – Biomarkers and Effectors of the Cellular Interactome in Cancer
Rak, J. W. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00021 · Cited by 216
Cancer pharmacogenomics: strategies and challenges
Wheeler, H. E., Maitland, M. L., Dolan, M. E., Cox, N. J., & Ratain, M. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3352 · Cited by 221
Intratumoral Heterogeneity of the Epigenome
Mazor, T., Pankov, A., Song, J. S., & Costello, J. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.009 · Cited by 217
“A seminal publication (Gerlinger et al., 2012) integrated the next-generation sequencing of tumors with principles from the clonal evolution theory of tumors.”
Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity
Li, L., Knútsdóttir, H., Hui, K., Weiss, M. J., He, J. P., Philosophe, B., Cameron, A. M., Wolfgang, C. L., Pawlik, T. M., Ghiaur, G., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.121490 · Cited by 216
“While understudied in human CCA, genetic intratumor heterogeneity has been recognized in other human cancers, such as renal cell carcinoma and HCC (7, 8, 10).”
BackgroundTherapeutic strategies targeting cancer stem cells
Yoshida, G. J., & Saya, H. (2015) · Cancer Science · doi:10.1111/cas.12817 · Cited by 222
Voss, M. H., Hakimi, A. A., Pham, C. G., Brannon, A. R., Chen, Y., Cunha, L. F., Akın, O., Liu, H., Takeda, S., Scott, S. N., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2345 · Cited by 219
The Consequences of Chromosome Segregation Errors in Mitosis and Meiosis
Potapova, T., & Gorbsky, G. J. (2017) · Biology · doi:10.3390/biology6010012 · Cited by 238
The future of personalised radiotherapy for head and neck cancer
Caudell, J. J., Torres–Roca, J. F., Gillies, R. J., Enderling, H., Kim, S., Rishi, A., Moros, E. G., & Harrison, L. B. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30252-8 · Cited by 214
The Role of Cancer Stem Cells in Radiation Resistance
Arnold, C. R., Mangesius, J., Skvortsova, I., & Ganswindt, U. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00164 · Cited by 226
Histologic subtype classification of non-small cell lung cancer using PET/CT images
Han, Y. K., Ma, Y., Wu, Z., Zhang, F., Zheng, D., Liu, X., Tao, L., Liang, Z., Yang, Z., Li, X., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04771-5 · Cited by 218
Tsimberidou, A. M., Wen, S., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S. A., Naing, A., Jankú, F., Aldape, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0603 · Cited by 210
Peng, Z., Liu, T., Wei, J., Wang, A., He, Y., Yang, L., Zhang, X., Fan, N., Luo, S., Li, Z., et al. (2021) · 癌症：英文版 · doi:10.1002/cac2.12214 · Cited by 218
Metastatic progression of breast cancer: insights from 50 years of autopsies
Cummings, M. C., Simpson, P. T., Reid, L., Jayanthan, J., Skerman, J., Song, S., Reed, A. E. M., Kutasovic, J. R., Morey, A. L., Marquart, L., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4288 · Cited by 210
Evolutionary foundations for cancer biology
Aktipis, A., & Nesse, R. M. (2013) · Evolutionary Applications · doi:10.1111/eva.12034 · Cited by 207
An analysis of genetic heterogeneity in untreated cancers
Reiter, J. G., Baretti, M., Gerold, J. M., Makohon-Moore, A. P., DAUD, A. I., Iacobuzio–Donahue, C. A., Azad, N. S., Kinzler, K. W., Nowak, M. A., & Vogelstein, B. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0185-x · Cited by 213
Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model
Zhang, Z., Shiratsuchi, H., Lin, J., Chen, G., Reddy, R. M., Azizi, E., Fouladdel, S., Chang, A. C., Lin, L., Jiang, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2592 · Cited by 207
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
Kuiper, J. L., Heideman, D. A. M., Thunnissen, E., Paul, M. A., van Wijk, A. W., Postmus, P. E., & Smit, E. F. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.016 · Cited by 210
The biology and mathematical modelling of glioma invasion: a review
Alfonso, J. C. L., Talkenberger, K., Seifert, M., Klink, B., Hawkins-Daarud, A. J., Swanson, K. R., Hatzikirou, H., & Deutsch, A. (2017) · Journal of The Royal Society Interface · doi:10.1098/rsif.2017.0490 · Cited by 206
Understanding tumor ecosystems by single-cell sequencing: promises and limitations
Ren, X., Kang, B., & Zhang, Z. (2018) · Genome biology · doi:10.1186/s13059-018-1593-z · Cited by 220
Glioblastoma Multiforme: A Look Inside Its Heterogeneous Nature
Inda, M.-D.-M., Bonavia, R., & Seoane, J. (2014) · Cancers · doi:10.3390/cancers6010226 · Cited by 222
The coming decade in precision oncology: six riddles
Wahida, A., Buschhorn, L., Fröhling, S., Jost, P. J., Schneeweiß, A., Lichter, P., & Kurzrock, R. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00529-3 · Cited by 224
“Finally, as different clones may bear both overlapping and distinct molecular alterations 70 , the concept of targeting convergent pathways may be called into question as alterations activated in different clones cannot converge.”
Zhang, H., Graham, C. M., Elci, O. U., Griswold, M., Zhang, X., Khan, M., Pitman, K. T., Caudell, J. J., Hamilton, R. D., Ganeshan, B., et al. (2013) · Radiology · doi:10.1148/radiol.13130110 · Cited by 206
Circulating Tumor Cells: A Multifunctional Biomarker
Yap, T. A., Lorente, D., Omlin, A. G., Olmos, D., & Bono, J. S. D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2664 · Cited by 214
Cancer: Evolution Within a Lifetime
Gerlinger, M., McGranahan, N., Dewhurst, S. M., Burrell, R. A., Tomlinson, I. P. M., & Swanton, C. (2014) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092314 · Cited by 210
Self-citationRietbergen, M. M., Leemans, C. R., Bloemena, E., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27821 · Cited by 206
Spatial biology of cancer evolution
Seferbekova, Z., Lomakin, A., Yates, L. R., & Gerstung, M. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00553-x · Cited by 227
The von Hippel-Lindau Tumor Suppressor Gene
Elias, R. M., Zhang, Q. H., & Brugarolas, J. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000480 · Cited by 210
Hsieh, J. J.-D., Chen, D., Wang, P. I., Marker, M., Redzematovic, A., Chen, Y., Selçuklu, S. D., Weinhold, N., Bouvier, N., Huberman, K. H., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.10.007 · Cited by 209
ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress
Neumann, M. H., Bender, S., Krahn, T., & Schlange, T. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.05.002 · Cited by 216
“therapy) liquid biopsy may allow longitudinal disease surveillance to monitor developing tumor heterogeneity [5].”
BackgroundMeiser, P., Knolle, M. A., Hirschberger, A., de Almeida, G. P., Bayerl, F., Lacher, S. B., Pedde, A., Flommersfeld, S., Hönninger, J., Stark, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.008 · Cited by 208
Liu, X., Peng, T., Xu, M., Lin, S., Hu, B., Chu, T., Liu, B., Xu, Y., Ding, W., Li, L., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01596-9 · Cited by 240
“Previous studies using multi-region profiling to decode the spatial patterns of heterogeneity were limited by the small number of regions analyzed per tumor [115].”
BackgroundWin, T., Miles, K. A., Janes, S. M., Ganeshan, B., Shastry, M., Endozo, R., Meagher, M., Shortman, R. I., Wan, S., Kayani, I. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1307 · Cited by 203
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Shin, H., Choi, Y., Yun, J. W., Kim, N. K. D., Kim, S., Jeon, H. J., Nam, J., Lee, C., Ryu, D., Kim, S. C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01470-y · Cited by 204
Zhang, C., Zhang, J. J., Xu, F.-P., Wang, Y.-G., Xie, Z., Su, J., Dong, S., Nie, Q., Shao, Y. W., Zhou, Q. H., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.031 · Cited by 203
Bulusu, K. C., Guha, R., Mason, D. J., Lewis, R. P., Muratov, E. N., KalantarMotamedi, Y., Cokol, M., & Bender, A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.003 · Cited by 208
Wang, P., Bahreini, A., Gyanchandani, R., Lucas, P. C., Hartmaier, R. J., Watters, R. J., Jonnalagadda, A. R., Bittar, H. E. T., Berg, A., Hamilton, R. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1534 · Cited by 200
“gene ultimately targeting the same phenotype (41).”
Scalable whole-genome single-cell library preparation without preamplification
Zahn, H., Steif, A., Laks, E., Eirew, P. D., VanInsberghe, M. A., Shah, S. P., Aparicio, S. A. J. R., & Hansen, C. L. (2017) · Nature Methods · doi:10.1038/nmeth.4140 · Cited by 199
Tanaka, N., Kanatani, S., Tomer, R., Sahlgren, C., Kronqvist, P., Kaczyńska, D., Louhivuori, L. M., Kis, L. L., Lindh, C., Mitura, P., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0139-0 · Cited by 202
The challenge of targeting cancer stem cells to halt metastasis
Agliano, A., Calvo, A., & Box, C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.003 · Cited by 201
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma
Hedberg, M. L., Goh, G., Chiosea, S. I., Bauman, J. E., Freilino, M. L., Zeng, Y., Wang, L., Diergaarde, B. B., Gooding, W. E., Lui, V. W. Y., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82066 · Cited by 208
“Cumulative evidence implicates a complex, nonlinear, branched evolution model of subclonal populations within tumors that defines dynamic processes that likely mediate the expansion of minor subclones under the selective pressure of therapy, culminating in metachronous recurrences that are often treatment resistant (1…”
BackgroundElghool, A., Basrawi, F., Ibrahim, T. K., et al. (2016) · Energy Conversion and Management · doi:10.1016/j.enconman.2016.12.046 · Cited by 200
Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes
Meeks, J. J., Al‐Ahmadie, H. A., Faltas, B. M., Taylor, J. A., Flaig, T. W., DeGraff, D. J., Christensen, E., Woolbright, B. L., McConkey, D. J., & Dyrskjøt, L. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0304-1 · Cited by 207
Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non–Small-Cell Lung Cancer
Bai, H., Wang, Z., Chen, K., Zhao, J., Lee, J. J., Wang, S., Zhou, Q., Zhuo, M., Mao, L., An, T., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3744 · Cited by 199
A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
Meric‐Bernstam, F., Johnson, A. M., Holla, V. R., Bailey, A. M., Brusco, L., Chen, K., Routbort, M. J., Patel, K. P., Zeng, J., Kopetz, S., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv098 · Cited by 202
PDXNET Consortium, Woo, X. Y., EurOPDX Consortium, Giordano, J., Srivastava, A., Zhao, Z.-M., Lloyd, M. W., de Bruijn, R., Suh, Y.-S., Patidar, R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00750-6 · Cited by 190
Regulation of alternative splicing of CD44 in cancer
Procházka, L., Tesařı́k, R., & Tuřánek, J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.07.011 · Cited by 204
Kim, K.-T., Lee, H. W., Lee, H.-O., Song, H. J., Jeong, D. E., Shin, S., Kim, H., Shin, Y., Nam, D.-H., Jeong, B. C., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-0945-9 · Cited by 198
“0, Additional file 2: Figure S2A and Additional file 3: Table S1), suggesting that it might be a founder event in tumor evolution [7, 8].”
BackgroundResultInfluentialWakimoto, H., Tanaka, S., Curry, W. T., Loebel, F., Zhao, D., Tateishi, K., Chen, J., Klofas, L. K., Lelic, N., Kim, J. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3052 · Cited by 190
Metadata
- Authors
- Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., Varela, I., Phillimore, B., Begum, S., McDonald, N. Q., Butler, A., Jones, D., Raine, K., Latimer, C., Santos, C. R., Nohadani, M., Eklund, A. C., Spencer-Dene, B., Clark, G., Pickering, L., Stamp, G., Gore, M., Szallasi, Z., Downward, J., Futreal, P. A., & Swanton, C.
- Affiliations
- Queen Mary University of London (GB)
- ORCID
- Gerlinger, Marco
- Rowan, Andrew J.
- Horswell, Stuart
- Larkin, James
- Endesfelder, David
- Gronroos, Eva
- Martinez, Pierre
- Tarpey, Patrick
- Varela, Ignacio
- Begum, Sharmin
- McDonald, Neil Q.
- Jones, David
- Raine, Keiran
- Latimer, Calli
- Eklund, Aron C.
- Pickering, Lisa
- Stamp, Gordon
- Downward, Julian
- Futreal, P. Andrew
- Swanton, Charles
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-08
- Volume
- 366
- Issue
- 10
- Pages
- 883-892
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4878653
- OpenAlex
- W2150575159
- Semantic Scholar
- b97108a8e1dd8cf67ff9f374a8237fabf4c96ad4
- Cited by
- 7,774
- References
- 35
- Citations by year
- 2026: 304 · 2025: 297 · 2024: 306 · 2023: 349 · 2022: 499 · 2021: 571 · 2020: 550 · 2019: 540 · 2018: 632 · 2017: 671 · 2016: 722 · 2015: 691 · 2014: 679 · 2013: 621 · 2012: 326
- FWCI
- 246.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion)
- Funders
- Wellcome Trust (079643)
- Cancer Research UK (10747, 15680)
- National Institute for Health and Care Research
- Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- intratumoral heterogeneity, tumor evolution, renal carcinoma, metastatic renal cell carcinoma, phylogenetic inference, mTOR, SETD2, PTEN, KDM5C, tumor suppressor mutations, allelic imbalance, aneuploidy, gene expression signatures, biomarker development, personalized medicine
- MeSH terms
- Everolimus, Biopsy, Carcinoma, Renal Cell, Chromosome Aberrations, Humans, Immunosuppressive Agents, Kidney, Kidney Neoplasms, Mutation, Neoplasm Metastasis, Phenotype, Phylogeny, Ploidies, Biomarkers, Tumor, Sequence Analysis, DNA, Genetic Heterogeneity, Evolution, Molecular, Sirolimus, Polymorphism, Single Nucleotide, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
